Protease Inhibitor Market Outlook, Segmentation and Growth Prospect 2017-2022
Protease inhibitors (PIs) are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis C. Protease inhibitors prevent viral replication selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors bind to the active site of the protease enzyme and prevent the maturation of the newly produced virions so that they remain non-infectious.
Protease inhibitors (PIs) are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis C. Protease inhibitors prevent viral replication selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors bind to the active site of the protease enzyme and prevent the maturation of the newly produced virions so that they remain non-infectious.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
growth. <strong>Protease</strong>s comprise drug targets for HIV <strong>and</strong> the clotting cascade as well as degradative enzymes such as<br />
elastase <strong>and</strong> dipeptidyl peptidases such as DPP IV. Many viral, bacterial <strong>and</strong> parasitic proteases are also potential drug<br />
targets <strong>and</strong> due to their lower homology to their mammalian orthologs, offer target opportunities to identify selective<br />
inhibitors that have minimal cross-reactivity with mammalian proteases.<br />
Geographically, the global protease inhibitor market spans North America, Latin America, Europe, Asia-Pacific,<br />
Middle-East & Africa. North America dominated the global market owing to rising prevalence of AIDS <strong>and</strong> immune<br />
related problems. APAC market also anticipated in significant growth in the global market owing The key players in<br />
the protease inhibitor market include CSL Ltd., Grifols S.A, Baxalta Incorporated, Octapharma AG, Kedrion S.p.A,<br />
China Biologic Products Inc., Biotest AG, LFB S.A, Bio Product Laboratory Ltd. <strong>and</strong> Sanquin.<br />
Get a Sample Copy of This Report @<br />
https://www.millioninsights.com/industry-reports/protease-inhibitor-pi-market/request-sample<br />
<strong>Market</strong> Segment:<br />
Geographically, this report is segmented into several key Regions, with production, consumption, revenue<br />
(million USD), market share <strong>and</strong> growth rate of <strong>Protease</strong> <strong>Inhibitor</strong>s in these regions, from 2012 to <strong>2022</strong> (forecast),<br />
covering<br />
• North America<br />
• Europe<br />
• China<br />
• Japan<br />
• Southeast Asia<br />
• India<br />
Global <strong>Protease</strong> <strong>Inhibitor</strong>s market competition by top manufacturers, with production, price, revenue (value)<br />
<strong>and</strong> market share for each manufacturer; the top players including<br />
• CSL Ltd. (Australia)<br />
• Grifols S.A (Spain)<br />
• Baxalta Incorporated (U.S.)<br />
• Octapharma AG (Switzerl<strong>and</strong>)<br />
• KedrionS.p.A (Italy)
Change language